National Crime Prevention Council’s Post

Affordable access to medicine is essential, but how can you ensure safety and quality when sourcing internationally? 💊 𝐖𝐡𝐲 𝐈𝐬𝐫𝐚𝐞𝐥? • Stringent Regulatory Standards: Israel's Ministry of Health enforces rigorous standards comparable to the FDA and EMA. • Medical Innovation: Israel ranks among the top countries for medical research and patents per capita. • Thorough Testing: All medications undergo clinical trials and quality assurance processes in accordance with ICH guidelines. • International Best Practices: Israel is a member of the OECD, adhering to international health and safety standards. 🔬 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 • Peace of Mind: Confidence in receiving medications that meet high safety standards, supported by organizations like the WHO. • Specialized Treatments: Access to treatments for chronic conditions like obesity, osteoporosis and cancer. • Regulatory Oversight: Meticulous oversight by Israeli authorities, ensuring product safety and compliance with international protocols. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 𝐡𝐞𝐫𝐞: https://lnkd.in/dtVnn44J #HealthcareExcellence #InternationalPharmacy #PatientSafety #MedicalInnovation #GlobalHealth

🌟 Daily Dose of Health Insights July 14🌟 🔹 Today's Highlight: Eby Rejects Dr. Bonnie Henry's Recommendation for Non-Prescription Access to Alternatives to Opioids "British Columbia Premier David Eby has rejected provincial health officer Dr. Bonnie Henry's recommendation to make alternatives to opioids and other street drugs available without a prescription. Eby acknowledged Henry's significant contributions during the COVID-19 pandemic but insisted that medical professionals must be involved in drug use for safety reasons. Dr. Henry argued that drug prohibition has failed, leading to a toxic, unregulated drug supply responsible for over 14,000 deaths in B.C. since a health emergency was declared eight years ago. She noted that the current system's barriers make it difficult to distribute safer-supply drugs via prescription alone. Eby emphasized the need to balance public health recommendations with political and practical realities, citing previous unimplemented recommendations on speed limits and alcohol prices." 🔎 Why Stay Updated? In the rapidly evolving field of healthcare, staying informed is crucial. Whether it's groundbreaking research, policy changes, local health events, or wellness tips, these updates are designed to enhance your understanding and keep you at the forefront of medical knowledge. 👩⚕️ Our Commitment to Community Health: At Terra Nova Medical Clinics, we believe in empowering our community with information. Knowledge is not just power; it's health. By sharing these updates, we hope to foster a well-informed community that is proactive about health and wellness. 📲 Join the Conversation: We encourage you to engage with our posts, share your thoughts, and spread awareness. Let's create a healthier, more informed community together. #TerraNovaMedical #StayInformed #OpioidCrisis #PublicHealth #BCPolitics #DrugPolicy #HarmReduction #SaferSupply #PrescriptionDrugs #BCGovernment https://lnkd.in/gx7Jquy4

U.S. Congressmen Don Davis (NC-01) and August Pfluger (TX-11) have introduced the bipartisan Old Drugs, New Cures Act, legislation to improve access to innovative, #affordable medication and tackle #healthdisparities in #rural and low-income communities across #America. “Reformulating existing drugs is an opportunity for #innovation to address unmet needs in an efficient and timely manner," GLI CEO Donna Cryer shared. “New uses for existing drugs have long been supported by the #raredisease community, for whom treatment options are highly limited. This bill presents an opportunity to advance #healthequity by driving innovation to Medicaid-eligible patients who experience high unmet medical needs.” Read more: https://lnkd.in/gvwuFH-4 #LiverHealth #policy #drugdevelopment #patientaccess #lifesaving

We have compiled the week's top news for you at Market Access Today! - New research has unveiled the substantial socioeconomic impact of cervical cancer in the UK. This discovery highlights the importance of reaching the World Health Organization's (WHO) elimination targets, as potential savings from achieving these goals are significant. (https://lnkd.in/dYfu3dvc) - For nearly three decades, the opioid crisis has been wreaking havoc in the U.S., despite the existence of effective treatments such as methadone and buprenorphine. These lifesaving medications, known to significantly decrease the risk of overdose and fatality, are underused due to pervasive stigma and systemic barriers. (https://lnkd.in/d_qVEFSA) - In a recent communication, the US Food and Drug Administration (FDA) underscored the escalating concern regarding data integrity issues within premarket submissions for medical devices. The agency noted a disturbing rise in fraudulent and unreliable laboratory testing data, compelling it to caution manufacturers and study sponsors to meticulously evaluate third-party entities conducting performance testing. (https://lnkd.in/dbpqHNHu) - In a landmark ruling by the Delaware federal court, AstraZeneca's legal challenge to Medicare's drug pricing reforms, as stipulated by the Inflation Reduction Act (IRA), was unequivocally dismissed. (https://lnkd.in/dWFxfsPA) - The NICE - National Institute for Health and Care Excellence has recently unveiled significant modifications to its cost-effectiveness evaluation criteria for new healthcare technologies. (https://lnkd.in/dn-nKvEV) Stay Informed, Stay Ahead with Market Access Today: marketaccesstoday.com #marketacces #reimbursementpolicies #patientaccessschemes #healthcareindustry #pricing #healtheconomics #pharmacoeconomics #health #pharmaceuticals #medicaldevices #HEOR #HTA #RWE #insights #trends #updates

The relationship between between Pharmacare policy and corporate interests is a complex one. The following article in Policy Options examines how Pharma companies and insurers influence policy development through strategies like lobbying and leveraging relationships with legislators. There's a need for transparency and a balanced approach that considers both public health and industry concerns. Collaborative efforts will be necessary to design a Pharmacare system that promises affordable access to medications while addressing the diverse interests at play. Read the full article for insights into navigating the complexities of pharmacare policy in Canada: https://lnkd.in/ggZAgU4t #Pharmacare #HealthcarePolicy #CorporateInterests #PublicHealth #Canada Nicole Serena, Daanyaal Bandukwala

Attention Washington providers: the Washington Prescription Drug Affordability Board (PDAB) is inviting providers to provide public oral or written input during their virtual meeting next Wednesday, September 18, from 8:30 AM to 12 PM Pacific. The full agenda can be found here: https://lnkd.in/dE7zTVFy You can find more information on the PDAB and how to submit oral/written comments, by visiting: https://lnkd.in/dCDFekCf Written comments may be submitted via email, and those interested in providing oral comments must notify the Board by Monday, September 16, 2024. The NICA Advocacy team is happy to assist with drafting comments. If you need assistance, please email advoacy@infusioncenter.org For a refresher on this issue, please refer to our "Government Price Setting" webpage here. https://lnkd.in/guqRbavh Thank you for your time and willingness to advocate for providers, patients, and the distribution channel! #InfusionProvider #MedicalProvider #Infusion #InfusionCenter #InfusionNurse #InfusionDeliveryChannel #MedicalInfusionProvider #FutureOfHealthcare

I won't be able to make this one, but for those of you also following the discourse on #DrugsShortages this is an excellent discussion to follow. This discussion and related resources from European Observatory on Health Systems and Policies helps to contextualise the discussion and bring home the point that every medicinal shortage affects lives. It also serves as a reminder that its not a case of "one size fits all" or that when new medicines come onto the marketplace, all others need to be dropped or "disinvested" unilaterally by the manufacturer. Its messy for all stakeholders when there is a breakdown in the supply chain. #PrimaryCare health professionals (especially GPs and #CommunityPharmacists) face major challenges without necessarily having the specialised knowledge to find #SuitableAlternatives for people already receiving treatment (as is the legal obligation across the EU). We are especially facing this as #PeopleLivingWithObesity who are not generally being treated as #Patients, but rather as #HealthConsumers without having our #LegalRights to #ContinuityOfTreatment acknowledged let alone respected. We can #DoBetter collectively! I hope this upcoming discussion will contribute a bit of #FoodForThought for those of us within the #Obesity community and more generally, on how we can ensure continuity of treatment (including pharmacotherapy) for Obesity patients. ❓ Curious about #LegalRights for #CitizensWithObesity? follow ADIPOSITAS PACT STICHTING | FONDATION PACTE ADIPOSITE (The Foundation for the Rights of Citizens with Obesity) BEUC - The European Consumer Organisation Pharmaceutical Group of the European Union (PGEU) KCE - Federaal Kenniscentrum voor de Gezondheidszorg - Centre Fédéral d'Expertise des Soins de Santé European Patients' Forum #DisQo Standing Committee of European Doctors (CPME)

This is a timely and great perspective on the 340B program and some suggested reforms. Reforms are long overdue. Here is the context of the Drug Channels summary. It makes the case in point that the 340B net margin realized nationally of $55B is more about bottom-line system revenue than it is about serving and passing the value on to our most vulnerable populations. *Hospitals that begin participating in the 340B program do not meaningfully increase their safety-net engagement. *The 340B program’s eligibility criteria poorly target safety-net providers. .*Contract pharmacies are less likely to be located in medically underserved areas, or areas with higher uninsured rates. It’s an especially timely reminder—especially because we just learned that the out-of-control 340B program grew at double-digit rates (again) in 2023". Scott Conard, MDGe BaiAdam FeinShawn GremmingerStacey RichterJeffrey HoganTrevor P.Liam LaFountainChris SkisakHouston Business Coalition on Health (HBCH)National Alliance of HealthcarPurchaser Coalitions Chris Deacon #340b Drug Channels Institute, an HMP Global company https://lnkd.in/g5CEnvns

⚠️ Alert: Lilly and Novo Nordisk are intensifying efforts against counterfeit drugs infiltrating obesity treatment. These fraudulent medications not only jeopardize treatment efficacy but also pose severe health risks. It's crucial to stay informed and cautious. Recent reports highlight the increase in counterfeit obesity treatments, emphasizing the need for heightened awareness and stringent regulatory measures. Patients and healthcare providers must remain vigilant to avoid these potentially harmful substances. Stay updated on this critical issue affecting healthcare safety. Read more about Lilly and Novo Nordisk's battle against counterfeit drugs here: https://lnkd.in/eSWdKPHC Together, let's ensure safe and effective treatments for everyone. #HealthcareSafety #CounterfeitDrugs #ObesityTreatment #PharmaNews

An increasing problem in Europe and other parts of the world, medicine shortages not only pose significant challenges for healthcare professionals, but they also put public health at risk by making timely, optimal treatment impossible. – Those in charge of finding solutions are often stuck between a rock and a hard place: a high level of protection against shortages is expensive, while too little protection can reduce the quality of care of patients. In practice, blanket policies tend to be applied to all medicines, but this is not always feasible or cost-effective. For instance, while stockpiling would offer a high level of protection against shortage, it would have been prohibitively expensive for governments to stockpile all medicines, write Marianne Jahre, Kim van Oorschot, Thomas Breugem, Iman Parsa, and Luk Van Wassenhove.